Results 61 to 70 of about 310,885 (317)
Background and objective Derlin 3 (DERL3) is downregulated in colorectal cancer (CRC) samples. Its level is closely linked to lymphatic metastasis or distant metastasis rate in CRC patients.
Dandan ZHOU +9 more
doaj +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha +10 more
wiley +1 more source
Decrypting cancer's spatial code: from single cells to tissue niches
Spatial transcriptomics maps gene activity across tissues, offering powerful insights into how cancer cells are organised, switch states and interact with their surroundings. This review outlines emerging computational, artificial intelligence (AI) and geospatial approaches to define cell states, uncover tumour niches and integrate spatial data with ...
Cenk Celik +4 more
wiley +1 more source
Long Noncoding RNA RGMB-AS1 Indicates a Poor Prognosis and Modulates Cell Proliferation, Migration and Invasion in Lung Adenocarcinoma. [PDF]
Lung cancer is the most common cause of cancer-related mortality worldwide. It is a complex disease involving multiple genetic and epigenetic alterations. The development of transcriptomics revealed the important role of long non-coding RNAs (lncRNAs) in
Ping Li +13 more
doaj +1 more source
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga +8 more
wiley +1 more source
Expression and clinical role of in lung adenocarcinoma
Objective To explore the levels of expression and clinical role of peroxiredoxin 6 ( PRDX6 ) in lung adenocarcinoma. Methods This retrospective study used a series of bioinformatics methods to detect the levels of expression of and mutations in the PRDX6
Zixin Chen +4 more
doaj +1 more source
The distinctive nature of adenocarcinoma of the lung
In recent years, many personalized treatments have been developed for NSCLC (non-small-cell lung cancer) patients. Among these, gefitinib, erlotinib, and afatinib are selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for patients with EGFR gene mutations, while crizotinib and ceritinib are two new tyrosine kinase inhibitors ...
openaire +6 more sources
Using multi‐omic characterization, we aimed to identify key regulators specific to squamous cell lung carcinoma (SqCC). SqCC‐specific differentially expressed genes were integrated with metabolics data. High expression of the creatine transporter SLC6A8, along with elevated creatine levels, appeared to be a distinct metabolic feature of SqCC.
Johan Staaf +10 more
wiley +1 more source
HLA-G Expression in Lung Adenocarcinoma Tissues and Its Relationship with Prognosis
Objective To investigate the expression of HLA-G and determine the prognostic value of HLA-G for lung adenocarcinoma. Methods The genomic alternation of HLA-G was analyzed using cBioPortal analytic tool.
ZHANG Wenlong +4 more
doaj +1 more source
Widespread rash in lung adenocarcinoma
A 68-year-old man is being treated with cisplatin-pemetrexed in the first line for bone metastatic lung adenocarcinoma. There is partial response and very good tolerance with no grade 3–4 toxicities. After six cycles of doublet therapy, the patient follows on pemetrexed maintenance. Six months later, he develops a hot and itchy rash with …
José Miguel Jurado +2 more
openaire +2 more sources

